Landscape → Rare Disease

Immune Thrombocytopenia Clinical Trial Landscape

Data updated: May 20, 2026

358 clinical trials tracked since 2008

Immune Thrombocytopenia is being studied across 358 clinical trials registered since 2008, with 142 programs currently active. The competitive pipeline includes 35 active Phase 3 trials, 86 active Phase 2 trials, and 34 active Phase 1 trials. Top industry sponsors include Novartis, argenx, Jiangsu HengRui Medicine Co., Ltd..

142 active

358 total (since 2008)

Phase 1 Active

72 total

Phase 2 Active

192 total

Phase 3 Active

109 total

Phase 4 Active

29 total

Top Industry Sponsors

Sorted by active Active Done Failed

Novartis 5 2 2

argenx 3 4 1

Jiangsu HengRui Medicine Co., Ltd. 3 4 1

Qilu Pharmaceutical Co., Ltd. 2 3 0

Chongqing Peg-Bio Biopharm Co., Ltd. 2 2 0

+ 10 more sponsors — see full table below

Featured Phase 3 Trials

NCT06449651 RECRUITING

A Study of Nipocalimab in Reducing the Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)

Janssen Research & Development, LLC n=39

NCT06533098 RECRUITING

A Study of Nipocalimab or Intravenous Immunoglobulin (IVIG) in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)

Janssen Research & Development, LLC n=50

NCT06722235 RECRUITING

A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

Takeda n=171

NCT06544499 RECRUITING

A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia

argenx n=69

NCT05653219 ACTIVE NOT RECRUITING

A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids

Novartis Pharmaceuticals n=152

+ 104 more Phase 3 trials — see full database below

Immune Thrombocytopenia — Trials Started by Year (last 10 years)

2016

2017

2018

2019

2020

2021

2022

2023

2024

2025

2026

TheraRadar.com

Full Trial Database

Complete sponsor table, every trial across all phases, plus competitive analytics. Sortable, filterable, exportable for Pro users.

Top Sponsors (all-time)

Novartis

argenx

Jiangsu HengRui Medicine Co., Ltd.

Qilu Pharmaceutical Co., Ltd.

Chongqing Peg-Bio Biopharm Co., Ltd.

Takeda

Johnson & Johnson

Sanofi

Chugai Pharmaceutical

Keymed Biosciences Co.Ltd

Active Trials by Phase

Phase 1

Phase 2

Phase 3

Phase 4

Enrollment Size Distribution

1-50

177

51-200

124

201-500

501-1k

1k+

All Industry Sponsors

Sorted by active Active Done Failed

Novartis 5 2 2

argenx 3 4 1

Jiangsu HengRui Medicine Co., Ltd. 3 4 1

Qilu Pharmaceutical Co., Ltd. 2 3 0

Chongqing Peg-Bio Biopharm Co., Ltd. 2 2 0

Takeda 2 1 0

Johnson & Johnson 2 0 0

Sanofi 2 0 0

Chugai Pharmaceutical 2 0 0

Keymed Biosciences Co.Ltd 2 0 0

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 2 0 0

Amgen 1 7 1

Pfizer 1 0 2

Principia Biopharma, a Sanofi Company 1 1 0

Eli Lilly 1 0 0

NCT06449651 RECRUITING

A Study of Nipocalimab in Reducing the Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)

Janssen Research & Development, LLC n=39

NCT06533098 RECRUITING

A Study of Nipocalimab or Intravenous Immunoglobulin (IVIG) in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)

Janssen Research & Development, LLC n=50

NCT06722235 RECRUITING

A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

Takeda n=171

NCT06544499 RECRUITING

A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia

argenx n=69

NCT05653219 ACTIVE NOT RECRUITING

A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids

Novartis Pharmaceuticals n=152

NCT07007962 RECRUITING

Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment

Sanofi n=60

NCT07559331 RECRUITING

High-Dose Dexamethasone Combined With Orelabrutinib Versus High-Dose Dexamethasone Combined With Placebo in Adult Patients With Newly Diagnosed Primary Immune Thrombocytopenia

Shandong University n=86

NCT07286032 RECRUITING

A Study to Evaluate the Efficacy and Safety of Hetrombopag Olamine Tablets Vs Placebo in Patients With Chemotherapy-Induced Thrombocytopenia

Jiangsu HengRui Medicine Co., Ltd. n=150

NCT06948318 RECRUITING

A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

Takeda n=150

NCT05653349 ACTIVE NOT RECRUITING

Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)

Novartis Pharmaceuticals n=226

NCT07194850 RECRUITING

A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP)

argenx n=24

NCT06759636 RECRUITING

A Study on the Treatment of CTIT of the Efficacy and Safety With Romiplostim N01 Compared to Recombinant Human Interleukin-11

The First Affiliated Hospital with Nanjing Medical University n=88

NCT07233213 RECRUITING

An Open-label Study of Intravenous Immunoglobulin (5%) for the Treatment of Primary Immune Thrombocytopenia

Grand Shuyang Life Sciences (Chengdu) Co., Ltd. n=36

NCT03937154 ACTIVE NOT RECRUITING

Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer

Amgen n=145

NCT07059000 RECRUITING

A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP)

Kedrion S.p.A. n=40

NCT07455006 NOT YET RECRUITING

Safety and Efficacy Study of QL0911 to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients

Qilu Pharmaceutical Co., Ltd. n=60

NCT07442513 RECRUITING

Comparison of Etamsylate Versus Placebo to Prevent Bleeding in HSCT

First Affiliated Hospital of Zhejiang University n=404

NCT04562766 ACTIVE NOT RECRUITING

Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP)

Principia Biopharma, a Sanofi Company n=232

NCT06962631 RECRUITING

V-IMMUNE® for Immune Thrombocytopenia

On Pharma Importadora, Exportadora e Distribuidora de Medicamentos LTDA. n=31

NCT04812925 ACTIVE NOT RECRUITING

A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia

argenx n=173

NCT06456528 RECRUITING

QL0911 for the Treatment of Cancer Treatment-Induced Thrombocytopenia

Qilu Pharmaceutical Co., Ltd. n=235

NCT07278908 NOT YET RECRUITING

Avatrombopag Combined With All-trans Retinoic Acid in the Treatment of Primary Immune Thrombocytopenia

Institute of Hematology & Blood Diseases Hospital, China n=248

NCT06507436 RECRUITING

The Phase III Clinical Study of Herombopag for the Treatment of Thrombocytopenia in Chronic Liver Disease Patients Undergoing Elective Invasive Surgery

Jiangsu HengRui Medicine Co., Ltd. n=101

NCT07216079 ACTIVE NOT RECRUITING

Rilzabrutinib for the Adult Participants With Chronic ITP Who Have Completed Phase 3 Study in Japan

Sanofi n=4

NCT07051915 NOT YET RECRUITING

The Holistic Study

Ostfold Hospital Trust n=220

NCT05325593 ACTIVE NOT RECRUITING

Romiplostim Plus Dexamethasone vs Dexamethasone in Patients With Newly Diagnosed Primary Immune Thrombocytopenia

Fundación Pública Andaluza para la gestión de la Investigación en Sevilla n=129

NCT06900920 RECRUITING

A Study of TQB3473 Tablets Compared to Placebo in the Treatment of Adult Primary Immune Thrombocytopenia

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. n=199

NCT05864014 ACTIVE NOT RECRUITING

Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Solid Tumors.

Jiangsu HengRui Medicine Co., Ltd. n=213

NCT06913374 NOT YET RECRUITING

The Study of Different Cycles of High-dose Dexamethasone in the Treatment of ITP

Shandong University n=118

NCT06202625 RECRUITING

Efficacy and Safety of Avatrombopag in the Treatment of Thrombocytopenia After Haplo-HSCT

Peking University People's Hospital n=142

NCT06440824 NOT YET RECRUITING

A Multicenter Randomized Controlled Study on the Treatment of Refractory CTIT With Romiplostim N01 Compared to Recombinant Human Thrombopoietin

Shandong University n=60

NCT06004856 RECRUITING

Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Chronic Primary Immune Thrombocytopenia

Beijing InnoCare Pharma Tech Co., Ltd. n=195

NCT04968899 RECRUITING

IgIV Plus Prednisone vs High-dose Dexamethasone for ITP

Assistance Publique - Hôpitaux de Paris n=272

NCT05338190 RECRUITING

Efficacy and Safety of Subcutaneous Belimumab or Placebo in Addition of Rituximab in Persistent or Chronic Immune Thrombocytopenia

Assistance Publique - Hôpitaux de Paris n=132

NCT07597395 NOT YET RECRUITING

ATRA for Management of Primary ITP

Peking University People's Hospital n=192

NCT05029635 COMPLETED

Phase III Study on HMPL-523 for Treatment of ITP

Hutchmed n=272

NCT04516967 COMPLETED

Avatrombopag for the Treatment of Thrombocytopenia in Pediatric Subjects With Immune Thrombocytopenia for ≥6 Months

Sobi, Inc. n=75

NCT05369208 COMPLETED

Evaluation of Avatrombopag for the Treatment of Thrombocytopenia in Japanese Adults With Chronic ITP

Sobi, Inc. n=19

NCT04225156 COMPLETED

A Long-term Study to Assess the Safety and Efficacy of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP).

argenx n=101

NCT03362177 COMPLETED

Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer

Amgen n=165

NCT04132050 COMPLETED

A Clinical Study in Patients With Chronic Idiopathic Thrombocytopenic Purpura in R788

Kissei Pharmaceutical Co., Ltd. n=34

NCT03939637 COMPLETED

Eltrombopag vs Standard Front Line Management for Newly Diagnosed Immune Thrombocytopenia (ITP) in Children

Baylor College of Medicine n=122

NCT04737850 COMPLETED

Hetrombopag for Pediatric Patients With Chronic Immune Thrombocytopenia

Jiangsu HengRui Medicine Co., Ltd. n=100

NCT03976882 COMPLETED

Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Subjects With Malignancy.

Jiangsu HengRui Medicine Co., Ltd. n=129

NCT04200456 TERMINATED

A Study to Evaluate the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)

UCB Biopharma SRL n=33

NCT04188379 COMPLETED

A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP).

argenx n=131

NCT06288932 COMPLETED

Outcome Study of Conventional Steroids Vs. Steroids Combined with Mycopehnolate in Newly Diagnosed Immune Thrombocytopenia Purpura.

National Institute of Blood and Marrow Transplant (NIBMT), Pakistan n=118

NCT04687072 COMPLETED

A Study to Evaluate the Efficacy and Safety of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia

argenx n=207

NCT05554913 COMPLETED

Evaluating the Efficacy and Safety of QL0911 in the Prevention of Chemotherapy- Induced Thrombocytopenia

Qilu Pharmaceutical Co., Ltd. n=63

NCT05422365 COMPLETED

Intravenous Immunoglobulin (IVIG, Bioven) Efficacy and Safety in Chronic Primary Immune Thrombocytopenia (ITP) in Adults

Biopharma Plasma LLC n=32

NCT05492409 COMPLETED

Study of the Safety and Immunogenicity of Long-term GNR-069 Therapy in ITP Patients

AO GENERIUM n=160

NCT02868099 COMPLETED

Efficacy and Safety of Romiplostim in Adult Subjects With Persistent or Chronic Immune Thrombocytopenia (ITP)

Kyowa Kirin China Pharmaceutical Co., Ltd. n=203

NCT05220878 COMPLETED

Comparative Study of Clinical Efficacy and Safety of GNR-069 and Nplate in Patients With ITP

AO GENERIUM n=160

NCT04596995 TERMINATED

A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)

UCB Biopharma SRL n=43

NCT03471078 COMPLETED

Avatrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Active Non-Hematological Cancers

Sobi, Inc. n=122

NCT05261646 WITHDRAWN

A Clinical Study of Hetrombopag Olamine Tablets in Adults Receiving 21-day Cycles of Chemotherapy for Solid Tumours, Who Are Delayed for at Least 1 Week From Their Scheduled Cycle Because of Chemotherapy-induced Thrombocytopenia

Jiangsu HengRui Medicine Co., Ltd.

NCT01428635 COMPLETED

Eltrombopag Olamine in Treating Thrombocytopenia in Patients With Chronic Myeloid Leukemia or Myelofibrosis Receiving Tyrosine Kinase Therapy

M.D. Anderson Cancer Center n=21

NCT04224688 TERMINATED

A Study to Assess the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)

UCB Biopharma SRL n=30

NCT05851027 COMPLETED

Evaluating the Efficacy and Safety of QL0911 in Chemotherapy- Induced Thrombocytopenia

Qilu Pharmaceutical Co., Ltd. n=50

NCT03809481 TERMINATED

Open-Label, Randomised, Active Controlled, Multi-Centre Phase 3 Study Safety and Efficacy of Danaparoid vs Argatroban

Aspen Global Incorporated n=7

NCT05621330 COMPLETED

Efficacy and Safety of QL0911 in Adult Patients With Chronic Primary Immune Thrombocytopenia

Qilu Pharmaceutical Co., Ltd. n=216

NCT03156452 COMPLETED

Newly Diagnosed Immune Thrombocytopenia Testing the Standard Steroid Treatment Against Combined Steroid & Mycophenolate

University Hospitals Bristol and Weston NHS Foundation Trust n=123

NCT05566990 COMPLETED

A Clinical Study to Evaluate the Efficacy and Safety of LIV-GAMMA SN Inj.10% in Primary Immune Thrombocytopenia (ITP)

SK Plasma Co., Ltd. n=34

NCT03222843 COMPLETED

Multicentre, Randomised Phase III Study of the Efficacy and Safety of Hetrombopag Olamine in Idiopathic Thrombocytopenic Purpura (ITP) Patient

Jiangsu HengRui Medicine Co., Ltd. n=424

NCT03515096 COMPLETED

Eltrombopag vs. rhTPO to Increase Platelet Level After HSCT

Shenzhen Second People's Hospital n=98

NCT02279173 COMPLETED

Long-term Study of Romiplostim in Thrombocytopenic Pediatric Patients With Immune Thrombocytopenia (ITP)

Amgen n=203

NCT02444728 TERMINATED

Cyclophosphamide and Hydroxychloroquine for Thrombocytopenia in SLE

Chinese SLE Treatment And Research Group n=50

NCT05046327 WITHDRAWN

Open-Label Study to Evaluate the Safety and Efficacy of Avatrombopag and Remission Rates in Adults With ITP of ≤6 Months

Sobi, Inc.

NCT03164915 COMPLETED

A Clinical Study to Evaluate the Efficacy and Safety of LIV-GAMMA SN Inj. in Primary Immune Thrombocytopenia (ITP)

SK Plasma Co., Ltd. n=37

NCT02578901 COMPLETED

American Trial Using Tranexamic Acid in Thrombocytopenia

University of Washington n=330

NCT03391856 TERMINATED

Prolonged Isolated Thrombocytopenia After Allo-SCT : N-acetyl-L-cysteine (NAC) Versus Supportive Therapy

Peking University People's Hospital n=15

NCT01663441 COMPLETED

A Phase Ⅲa Study of Genetically Modified Recombinant Human Interleukin-11

Beijing Northland Biotech. Co., Ltd. n=62

NCT04274452 WITHDRAWN

A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP)

argenx

NCT02487563 COMPLETED

Prospective Study of Patients With Thrombocytopenia Following HSCT

The First Affiliated Hospital of Soochow University n=97

NCT03326843 TERMINATED

Avatrombopag for the Treatment of Thrombocytopenia in Adults Scheduled for a Surgical Procedure

Sobi, Inc. n=4

NCT02391272 COMPLETED

A Multicenter Study on Recombinant Human Thrombopoietin in Management of ITP in Pregnancy

Shandong University n=31

NCT01071954 COMPLETED

A Study Evaluating the Safety and Efficacy of Long-term Dosing of Romiplostim in Thrombocytopenic Pediatric Patients With Immune (Idiopathic) Thrombocytopenia Purpura

Amgen n=66

NCT01821625 TERMINATED

Study of Quadruple Therapy With Eltrombopag for Chronic Hepatitis C

University of Texas Southwestern Medical Center n=7

NCT04070599 COMPLETED

Initial Hemato-immunological Profile on the Evolution of Immunological Thrombopenic Purpura.

University Hospital, Bordeaux n=70

NCT02859909 COMPLETED

This Clinical Study is to Test Efficacy and Safety of BT595 in Chronic Primary Immune Thrombocytopenia (ITP)

Biotest n=34

NCT02389621 COMPLETED

Safety and Efficacy Study of Lusutrombopag for Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Elective Invasive Procedures

Shionogi n=215

NCT00678587 TERMINATED

Eltrombopag To Reduce The Need For Platelet Transfusion In Subjects With Chronic Liver Disease And Thrombocytopenia Undergoing Elective Invasive Procedures

GlaxoSmithKline n=292

NCT00828750 COMPLETED

Clinical Evaluation of Eltrombopag in Chronic Idiopathic Thrombocytopenic Purpura (ITP)

GlaxoSmithKline n=19

NCT02649504 WITHDRAWN

Rituximab and Dexamethasone Followed by Mycophenolate Mofetil or Placebo in Patients With Immune Thrombocytopenia

Weill Medical College of Cornell University

NCT01972529 COMPLETED

Treatment of Thrombocytopenia in Patients With Chronic Liver DiseaseUndergoing an Elective Procedure

Eisai Inc. n=231

NCT01976104 COMPLETED

Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing an Elective Procedure

Eisai Inc. n=204

NCT01433978 TERMINATED

A Phase 3, Multicenter, Randomized, Double-blind,Active-controlled, Parallel-group Trial With an Open-labelExtension Phase to Evaluate the Efficacy and Safety of OralE5501 Versus Eltrombopag, in Adults With Chronic ImmuneThrombocytopenia (Idiopathic Thrombocytopenic Purpura)

Eisai Inc. n=24

NCT01438840 COMPLETED

Efficacy and Safety of Oral E5501 Plus Standard of Care for the Treatment of Thrombocytopenia in Adults With Chronic Immune Thrombocytopenia (Amendment 02)

Eisai Inc. n=49

NCT03343847 WITHDRAWN

Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Lymphoma.

Amgen

NCT02914054 COMPLETED

Therapy of Adults Affected by Idiopathic Thrombocytopenic Purpura With Dexamethasone

Isfahan University of Medical Sciences n=36

NCT00511147 COMPLETED

IGIV Study for Chronic ITP Patients Ages 3-70

Grifols Biologicals, LLC n=64

NCT01349790 COMPLETED

Efficacy and Safety of Immunoglobulin Intravenous (Human) 10% (NewGam) in Primary Immune Thrombocytopenia

Octapharma n=40

NCT01444417 COMPLETED

Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients

Amgen n=62

NCT01368211 TERMINATED

Mirasol-Treated Platelets - (Pathogen Reduction Extended Storage Study)

Terumo BCTbio n=16

NCT02063789 COMPLETED

An Open Phase 3 Study of IV-Globulin SN Inj.10% to Treat Immune Thrombocytopenia

Green Cross Corporation n=81

NCT02137681 WITHDRAWN

A Multicentre Investigation of 2 Cycles Rituximab Compared With Standard Regimen in Management of Steroid-Resistant/Relapsed Immune Thrombocytopenia （ITP）

Shandong University

NCT02203422 WITHDRAWN

A Multicenter Investigation of Recombinant Human Thrombopoietin (rhTPO) Combining Cyclosporin A Versus Cyclosporin A in Management of Steroid-Resistant/Relapsed Immune Thrombocytopenia （ITP）

Shandong University

NCT01506414 COMPLETED

Recombinant Human Thrombopoietin in Combination With Rituximab in Immune Thrombocytopenia (ITP)

Ming Hou n=91

NCT01525836 COMPLETED

rhTPO Combining Rituximab Versus Low-dose Rituximab in Management of ITP

Shandong University n=123

NCT01882127 WITHDRAWN

All-Trans Retinoic Acid (ATRA) Combining Dexamethasone Versus High-dose Dexamethasone for Initial Treatment of Primary Immune Thrombocytopenia (ITP)

Shandong University

NCT01734057 WITHDRAWN

Recombinant Human Thrombopoietin (rhTPO) Combining Rituximab Versus High-dose Dexamethasone for Initial Treatment of Primary Immune Thrombocytopenia (ITP)

Shandong University

NCT02351622 COMPLETED

Caffeic Acid Tablets as a Second-line Therapy for ITP

Shandong University n=103

NCT01734044 COMPLETED

rhTPO Combining Dexamethasone Versus High-dose Dexamethasone for Initial Treatment of ITP

Shandong University n=158

NCT02139501 COMPLETED

An Investigation of rhTPO With Different Frequencies in the Management of ITP

Shandong University n=48

NCT01598168 TERMINATED

Rivaroxaban for Treatment of Patients With Suspected or Confirmed Heparin-Induced Thrombocytopenia

McMaster University n=22

NCT01226524 TERMINATED

The Role of Traditional Chinese Medicine in the Treatment of Chronic Childhood Immune Thrombocytopenia (ITP)

Hadassah Medical Organization n=7

NCT01609452 WITHDRAWN

MONICA-SC: A Study to Evaluate the Efficacy, Safety and Tolerability of Blisibimod (A-623) Administration in Subjects With ITP

Anthera Pharmaceuticals

NCT01520909 COMPLETED

Study of a New Medication for Childhood Chronic Immune Thrombocytopenia (ITP), a Blood Disorder of Low Platelet Counts That Can Lead to Bruising Easily, Bleeding Gums, and/or Bleeding Inside the Body.

GlaxoSmithKline n=92

NCT00749112 COMPLETED

Alemtuzumab and Rituximab in the Treatment of Refractory Autoimmune Cytopenias

Hospital Universitario Dr. Jose E. Gonzalez n=19

NCT05070845 RECRUITING

Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia

Pfizer

NCT06721013 RECRUITING

A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia

Eli Lilly and Company

NCT07441720 RECRUITING

Safety and Efficacy of Umbilical Cord Blood Therapy for Cancer Therapy-Induced Thrombocytopenia (CTIT)

Zhejiang Cancer Hospital

NCT07421167 RECRUITING

A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP)

Novartis Pharmaceuticals

NCT07104565 RECRUITING

Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders

Incyte Corporation

NCT07043894 RECRUITING

Romiplostim N01 for Chemotherapy-Induced Thrombocytopenia in Pediatric Cancer Patients

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

NCT07549698 NOT YET RECRUITING

Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease

CRISPR Therapeutics AG

NCT07535645 NOT YET RECRUITING

Baricitinib for Post-HSCT Persistent Thrombocytopenia

Peking University People's Hospital

NCT07039422 RECRUITING

Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) Who Have Previously Benefited From Ianalumab

Novartis Pharmaceuticals

NCT05885555 ACTIVE NOT RECRUITING

A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of Therapies

Novartis Pharmaceuticals

NCT07043946 RECRUITING

A Phase 1b/2a Study of Budoprutug in Subjects With Immune Thrombocytopenia (ITP)

Climb Bio, Inc.

NCT07492693 RECRUITING

Efficacy and Safety of Hetrombopag in Preventing Chemotherapy-induced Thrombocytopenia in Gastrointestinal Tumors

Changhai Hospital

NCT06788691 RECRUITING

Luspatercept for Clonal Cytopenias of Uncertain Significance

Weill Medical College of Cornell University

NCT05772546 ACTIVE NOT RECRUITING

Avatrombopag vs. Placebo for CIT in GI Malignancies

Hanny Al-Samkari, MD

NCT07459114 NOT YET RECRUITING

TGD001 Treatment in Thrombotic Microangiopathies

TargED Biopharmaceuticals B.V.

NCT07446491 RECRUITING

A Study to Evaluate the Safety and Efficacy of PN20 in the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing an Elective Procedure

Chongqing Peg-Bio Biopharm Co., Ltd.

NCT07408648 NOT YET RECRUITING

A Clinical Study on the Efficacy and Safety of Hetrombopag in the Treatment of Thrombocytopenia Induced by Gynecological Tumor Therapy

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

NCT05980806 RECRUITING

A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia

Karyopharm Therapeutics Inc

NCT07297563 RECRUITING

Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)

Institute of Hematology & Blood Diseases Hospital, China

NCT07234019 RECRUITING

Rituximab Combining Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)

Institute of Hematology & Blood Diseases Hospital, China

NCT07400250 NOT YET RECRUITING

Phase II Study of Orelabrutinib in Combination With Romiplostim N01 in Patients With Primary Immune Thrombocytopenia (ITP) Who Have Received At Least One Prior Line of Therapy

Peking Union Medical College Hospital

NCT05599880 RECRUITING

The Investigate Efficacy and Safety Evaluation of Bortezomib in Patients With Relapsed/Refractory Immune Thrombocytopenia

Seoul National University Hospital

NCT05023915 ACTIVE NOT RECRUITING

A Multicenter Randomized Open-label Study of Diammonium Glycyrrhizinate Enteric-coated Capsule Plus DXM Versus DXM in Treatment of ITP

Shandong University

NCT07362238 RECRUITING

Daratumumab Versus Rituximab in the Management of Pediatric Primary Immune Thrombocytopenia (ITP)

Institute of Hematology & Blood Diseases Hospital, China

NCT07362199 RECRUITING

Anti-CD38 Monoclonal Antibody Combined With Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)

Institute of Hematology & Blood Diseases Hospital, China

NCT07294365 RECRUITING

A Study of DZD8586 in Adults With Primary Immune Thrombocytopenia (ITP) (TAI-SHAN11)

Dizal Pharmaceuticals

NCT06929299 RECRUITING

A Phase Ib/II Clinical Trial of Multiple Doses of STSA-1301 Subcutaneous Injection in Healthy Subjects and Patients With Immune Thrombocytopenia (ITP)

Jiangsu BioJeTay Biotechnology Co., Ltd.

NCT07334093 NOT YET RECRUITING

A Study of Hetrombopag Combined With rhTPO in the Treatment of Cancer Therapy-induced Thrombocytopenia (CTIT) in Solid Tumor Patients.

Sun Yat-sen University

NCT07175493 RECRUITING

A Study of CM336 in Patients With Relapsed or Refractory Autoimmune Cytopenia

Keymed Biosciences Co.Ltd

NCT07257809 RECRUITING

Herombopag Treated T-DM1 Induced Platelet Reduction

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

NCT06168851 RECRUITING

Anti-CD38 Antibody Treating Pediatric Primary Immune Thrombocytopenia (ITP)

Institute of Hematology & Blood Diseases Hospital, China

NCT07252375 NOT YET RECRUITING

A Clinical Study of Hetrombopag for Prevention of Thrombocytopenia Induced by Gemcitabine Plus Cisplatin in the Treatment of Nasopharyngeal Carcinoma

Fujian Cancer Hospital

NCT07243418 NOT YET RECRUITING

Hetrombopag for the Prevention of ADC-Induced Thrombocytopenia in Breast Cancer: An Exploratory, Dual-Cohort, Phase 2 Study

Fujian Cancer Hospital

NCT07196163 NOT YET RECRUITING

An Exploratory Study of Golidocitinib in Adult Patients With ITP

Peking University People's Hospital

NCT07065968 RECRUITING

The Efficacy and Safety of Combined Teriflunomide and High-dose Dexamethasone in Newly Diagnosed Primary Immune Thrombocytopenia (TEMPO-2)

Peking University People's Hospital

NCT01966367 ACTIVE NOT RECRUITING

CD34+ (Non-Malignant) Stem Cell Selection for Patients Receiving Allogeneic Stem Cell Transplantation

Diane George

NCT04099966 RECRUITING

AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion

Mitchell Cairo

NCT06776510 RECRUITING

A Clinical Study of NAD in the Treatment of Immune Thrombocytopenia

Institute of Hematology & Blood Diseases Hospital, China

NCT06838962 RECRUITING

Anti-CD38 Antibody Treating Children With Primary Immune Thrombocytopenia (ITP)

Institute of Hematology & Blood Diseases Hospital, China

NCT05983952 RECRUITING

Anti-CD38 Antibody Treating APS With Thrombocytopenia

Institute of Hematology & Blood Diseases Hospital, China

NCT07095127 RECRUITING

Safety, Tolerability, and Efficacy of NVG-2089 in Participants With Immune Thrombocytopenia

Nuvig Therapeutics, Inc.

NCT07083739 NOT YET RECRUITING

A Study on the Safety and Efficacy of TQB3473 Tablets in the Treatment of Persistent or Chronic Primary Immune Thrombocytopenia (ITP) in Adults

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

NCT07064889 NOT YET RECRUITING

The Combination of Upadacitinib and High-dose Dexamethasone as First-line Treatment in Adult Immune Thrombocytopenia

Peking University People's Hospital

NCT07063225 RECRUITING

Romiplostim N01 for Chemotherapy-induced Thrombocytopenia

Institute of Hematology & Blood Diseases Hospital, China

NCT07063199 RECRUITING

Anti-CD38 Antibody Treating Elderly Patients With Primary Immune Thrombocytopenia (ITP)

Institute of Hematology & Blood Diseases Hospital, China

NCT07057778 NOT YET RECRUITING

Iguratimod Plus Low-dose Rituximab vs Low-dose Rituximab in Corticosteroid-resistant or Relapsed ITP

Peking University People's Hospital

NCT05757570 ACTIVE NOT RECRUITING

An Open-label Study of Povetacicept in Participants With Autoimmune Cytopenias

Alpine Immune Sciences, Inc.

NCT06412497 RECRUITING

MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.

Masonic Cancer Center, University of Minnesota

NCT07019545 NOT YET RECRUITING

A PHASE II TRIAL AIMING TO INVESTIGATE THE SAFETY AND CLINICAL ACTIVITY OF BELANTAMAB MAFODOTIN IN ADULT PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA PREVIOUSLY TREATED WITH A THROMBOPOIETIN RECEPTOR AGONIST AND/OR RITUXIMAB AFTER CORTICOSTEROID FIRST-LINE THERAPY

Hellenic Society of Hematology

NCT07017725 RECRUITING

A Dose-escalation Study Followed by a Dose Optimal Study to Evaluate the Safety and Efficacy of CID-103 in Adults With Chronic Immune Thrombocytopenia

CASI Pharmaceuticals, Inc.

NCT05562882 ACTIVE NOT RECRUITING

A Clinical Trial to Assess Safety and Efficacy of Daratumumab in the Treatment of Primary Immune Thrombocytopenia

Institute of Hematology & Blood Diseases Hospital, China

NCT06992128 RECRUITING

Romiplostim N01 Combined With Glucocorticoids as the First-line Treatment for Newly Diagnosed Adult Primary Immune Thrombocytopenia: A Multicenter, Interventional Trial

Institute of Hematology & Blood Diseases Hospital, China

NCT06853444 RECRUITING

A Phase 1/2 Study of ESG206 in Patients With Primary Immune Thrombocytopenia

Shanghai Escugen Biotechnology Co., Ltd

NCT05998759 RECRUITING

Telitacicept for the Treatment of Connective Tissue Disease-associated Thrombocytopenia

Beijing Hospital

NCT06594146 ACTIVE NOT RECRUITING

Study of CM313 (SC) Injection in Subjects With Primary Immune Thrombocytopenia (ITP)

Keymed Biosciences Co.Ltd

NCT06898983 NOT YET RECRUITING

Efficacy and Safety Study of Romiplostim N01 for Cancer Treatment-induced Thrombocytopenia (CTIT) in the Treatment of Leukemia

Anhui Provincial Hospital

NCT06799611 RECRUITING

An Open, Exploratory Clinical Study of CM336 in the Treatment of Immune Thrombocytopenia

Institute of Hematology & Blood Diseases Hospital, China

NCT04600960 RECRUITING

Eltrombopag for Chemotherapy-induced Thrombocytopenia

Institute of Hematology & Blood Diseases Hospital, China

NCT05236582 RECRUITING

Herombopag for Chemotherapy-induced Thrombocytopenia

Institute of Hematology & Blood Diseases Hospital, China

NCT05199909 RECRUITING

Safety and Efficacy of Zanubrutinib in the Treatment of Antiphospholipid Syndrome With Secondary Thrombocytopenia

Institute of Hematology & Blood Diseases Hospital, China

NCT06281327 RECRUITING

Avatrombopag in the Treatment of Pediatric Immune Thrombocytopenia

Institute of Hematology & Blood Diseases Hospital, China

NCT05218226 RECRUITING

Avatrombopag for Chemotherapy-induced Thrombocytopenia

Institute of Hematology & Blood Diseases Hospital, China

NCT06094881 RECRUITING

A Prospective, One-arm and Open Clinical Study of Obinutuzumab in the Treatment of Pediatric Primary Immune Thrombocytopenia (ITP)

Institute of Hematology & Blood Diseases Hospital, China

NCT05214391 RECRUITING

A Prospective, One-arm and Open Clinical Study of Zanubrutinib in the Treatment of Immune Thrombocytopenia

Institute of Hematology & Blood Diseases Hospital, China

NCT04993885 RECRUITING

Avatrombopag in the Treatment of Adult Immune Thrombocytopenia With Autoantibodies

Institute of Hematology & Blood Diseases Hospital, China

NCT05995054 RECRUITING

A Prospective, One-arm and Open Clinical Study of Obinutuzumab in the Treatment of Immune Thrombocytopenia

Institute of Hematology & Blood Diseases Hospital, China

NCT06531018 RECRUITING

Role of Eltrombopag as First Line Therapy in Primary Immune Thrombocytopenia.

Renata PLC

NCT06686927 RECRUITING

Study on Glucocorticoid Combined With Gamma Globulin and Ropristine N01 in Treatment of Initial Severe ITP

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

NCT06199089 ACTIVE NOT RECRUITING

A Randomized, Double-blind, Placebo-controlled, and Multi-center Clinical Study of CM313 in the Treatment of Immune Thrombocytopenia

Institute of Hematology & Blood Diseases Hospital, China

NCT06673498 RECRUITING

Lusutrombopag Combined With Recombinant Human Thrombopoietin for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Destined to Undergo Elective Invasive Surgery

Anhui Provincial Hospital

NCT06658834 RECRUITING

A Study of Romiplostim N01 as the First-line Treatment for Newly Diagnosed Adult Patients With ITP

Institute of Hematology & Blood Diseases Hospital, China

NCT06577909 RECRUITING

Prednisone Plus IVIg vs. Prednisone for ITP During Pregnancy

Peking University People's Hospital

NCT06352281 RECRUITING

Efficacy and Safety of CAR-T Cells Therapy for Chronic or Refractory Primary Immune Thrombocytopenia (ITP)

920th Hospital of Joint Logistics Support Force of People's Liberation Army of China

NCT06478537 RECRUITING

TPO-RA Treatment on Immune Tolerance Induction of ITP Patients With Sustained Platelet Recovery After Treatment Termination

Peking Union Medical College Hospital

NCT06433830 RECRUITING

Hetrombopag for the Thrombocytopenia Induced by Concurrent Chemoradiotherapy

Sir Run Run Shaw Hospital

NCT05944211 NOT YET RECRUITING

Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia(CIT) in Patients With Acute Myeloid Leukemia

RenJi Hospital

NCT05369364 NOT YET RECRUITING

The Combination of Zanubrutinib and High-dose Dexamethasone as First-line Treatment in Adult Immune Thrombocytopenia

Peking University People's Hospital

NCT02912208 ACTIVE NOT RECRUITING

Eltrombopag for the Treatment of Thrombocytopenia Due to Low- and Intermediate Risk Myelodysplastic Syndromes

Associazione Qol-one

NCT05126004 NOT YET RECRUITING

AZA Combined With NAC for PIT After HSCT

The First Affiliated Hospital of Soochow University

NCT07586826 RECRUITING

Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gynecologic, Breast, or Lung Solid Tumors

Peking University People's Hospital

NCT07586813 RECRUITING

Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gastrointestinal Solid Tumors

Peking University People's Hospital

NCT07025512 WITHDRAWN

177Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) With Bone Marrow Involvement and Cytopenia

M.D. Anderson Cancer Center

NCT04673266 COMPLETED

Using Romiplostim to Treat Low Platelet Counts During Chemotherapy in People With Lymphoma

Memorial Sloan Kettering Cancer Center

NCT04965597 COMPLETED

Treosulfan-Based Conditioning Regimen Before a Blood or Bone Marrow Transplant for the Treatment of Bone Marrow Failure Diseases (BMT CTN 1904)

Fred Hutchinson Cancer Center

NCT06435845 TERMINATED

Phase 2 Study on the Pharmacokinetics and Safety of RLYB212 in Pregnant Women at Higher Risk for HPA-1a Alloimmunization

Rallybio

NCT03395210 COMPLETED

A Study of Rilzabrutinib in Adult Patients With Immune Thrombocytopenia (ITP)

Principia Biopharma, a Sanofi Company

NCT03664518 COMPLETED

to Evaluate the Efficacy and Safety of Eltrombopag for Immune Thrombocytopenia With Chronic HBV Infection

Institute of Hematology & Blood Diseases Hospital, China

NCT00975819 COMPLETED

Safety and Efficacy Study of Sirolimus in Complicated Vascular Anomalies

Denise Martin Adams

NCT00861692 COMPLETED

Clinical Management of Argatroban in Patients With Heparin Induced Thrombocytopenia Type II

Tanabe Pharma Corporation

NCT06287567 COMPLETED

Lusutrombopag in the Treatment of Immune Thrombocytopenia (ITP)

Institute of Hematology & Blood Diseases Hospital, China

NCT05502783 TERMINATED

Using Fostamatinib to Treat Post-Hematopoietic Stem Cell Transplant Immune-mediated Cytopenias

National Heart, Lung, and Blood Institute (NHLBI)

NCT05785819 TERMINATED

A Phase 2 Study of VLX-1005 Versus Placebo in Suspected Heparin Induced Thrombocytopenia

Veralox Therapeutics

NCT05509582 WITHDRAWN

Extension Study (Extended Access) of Syk-inhibition Using Fostamatinib to Treat Posttransplant Immune-mediated Cytopenias

National Heart, Lung, and Blood Institute (NHLBI)

NCT05086744 TERMINATED

Basket Study to Assess Efficacy, Safety and PK of Iptacopan (LNP023) in Autoimmune Benign Hematological Disorders

Novartis Pharmaceuticals

NCT04669600 COMPLETED

A Phase 2a Study Evaluating BIVV020 in Adults With Persistent/Chronic Immune Thrombocytopenia (ITP)

Bioverativ, a Sanofi company

NCT03838354 COMPLETED

A Clinical Trial of Chidamide in the Management of Refractory ITP

Shandong University

NCT06176235 WITHDRAWN

Teriflunomide Plus High-dose Dexamethasone as First-line Treatment in Newly Diagnosed Primary Immune Thrombocytopenia

Peking University People's Hospital

NCT03333486 TERMINATED

Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer

Roswell Park Cancer Institute

NCT04278924 COMPLETED

A Study of TAK-079 in Adults With Persistent/Chronic Primary Immune Thrombocytopenia

Takeda

NCT00860600 COMPLETED

Safety and Efficacy Study of PG2 to Treat Idiopathic Thrombocytopenic Purpura (ITP) Patients

PhytoHealth Corporation

NCT03866577 TERMINATED

Safety and Tolerability of M254 in Healthy Volunteers and Immune Thrombocytopenic Purpura (ITP) Patients

Momenta Pharmaceuticals, Inc.

NCT04346654 COMPLETED

A Study to Assess Efficacy and Safety of Eltrombopag in Combination With a Short Course of Dexamethasone in Patients With Newly Diagnosed ITP

Novartis Pharmaceuticals

NCT03712618 TERMINATED

The SOLID Platelet Study

National Institutes of Health Clinical Center (CC)

NCT05694767 COMPLETED

A Prospective, One-arm and Open Clinical Study of CM313 in the Treatment of Immune Thrombocytopenia

Institute of Hematology & Blood Diseases Hospital, China

NCT05944809 COMPLETED

The Effect of Prophylactic TPO Combined with BMS-IMRT to Esophageal Cancer Patients

JIANYANG WANG

NCT03524612 COMPLETED

A Study to Assess the Ability of Eltrombopag to Induce Sustained Response Off Treatment in Subjects With ITP

Novartis Pharmaceuticals

NCT02052882 COMPLETED

Study of Romiplostim for Chemotherapy Induced Thrombocytopenia

Memorial Sloan Kettering Cancer Center

NCT04812483 COMPLETED

Immunomodulation With Eltrombopag in ITP

University Children's Hospital Basel

NCT03638817 COMPLETED

Perioperative Eltrombopag in Patients With Inherited Thrombocytopenia

University Hospital, Toulouse

NCT04056195 COMPLETED

Study of Oral SKI-O-703, SYK Inhibitor, in Patients With Persistent and Chronic Immune Thrombocytopenia (ITP)

Oscotec Inc.

NCT02868060 COMPLETED

Evaluating the Pharmacokinetics and Pharmacodynamics of Romiplostim in Patients With Immune Thrombocytopenia (ITP)

Kyowa Kirin China Pharmaceutical Co., Ltd.

NCT04083014 COMPLETED

Single-dose Anti-CD20 Antibody With Bortezomib for Relapsed Refractory Autoimmune Hemolytic Anemia

Peking Union Medical College Hospital

NCT03830749 COMPLETED

Safety and Efficacy of Eltrombopag Plus Pulsed Dexamethasone for Subjects With Idiopathic Thrombocytopenic Purpura

Humanity & Health Medical Group Limited

NCT02718716 COMPLETED

Study to Evaluate Safety, Tolerability and Efficacy of UCB7665 in Subjects With Primary Immune Thrombocytopenia

UCB Biopharma SRL

NCT04543279 TERMINATED

Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe Thrombocytopenia

Washington University School of Medicine

NCT00961064 COMPLETED

A Pilot Study of a Thrombopoietin-Receptor Agonist, Eltrombopag, in Patients With Low to Int-2 Risk Myelodysplastic Syndrome (MDS)

National Heart, Lung, and Blood Institute (NHLBI)

NCT04917679 COMPLETED

Eltrombopag Plus Diacerein vs Eltrombopag in Adult ITP

Qilu Hospital of Shandong University

NCT05279872 COMPLETED

A Study of Zanubrutinib in Patients With ITP

Peking University People's Hospital

NCT01000051 COMPLETED

Eltrombopag for Post Transplant Thrombocytopenia

M.D. Anderson Cancer Center

NCT03513328 COMPLETED

Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation

University of Florida

NCT03754634 COMPLETED

A Prospective, Open, Multicenter Clinical Trial of Eltrombopag Combined With Diacerein in Eltrombopag-inefficient or Relapsed ITP

Shandong University

NCT03102593 COMPLETED

A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With ITP

argenx

NCT04631211 TERMINATED

Thrombosomes® in Bleeding Thrombocytopenic Patients Study

Cellphire Therapeutics, Inc.

NCT05393999 WITHDRAWN

SABRE: A Single-arm Prospective Study Measuring Safety and Tolerability of SARS-CoV-2 Neutralising Antibodies in High-risk Populations

Imperial College Healthcare NHS Trust

NCT00614523 COMPLETED

Romiplostim Treatment of Thrombocytopenia in Subjects With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Amgen

NCT01143038 COMPLETED

Interventional Study in Adults With Immune Thrombocytopenia Purpura (ITP) Receiving Romiplostim

Amgen

NCT02074436 TERMINATED

PRevention Of BLeeding in hEmatological Malignancies With Antifibrinolytic (Epsilon Aminocaproic Acid)

Emory University

NCT03303950 TERMINATED

Allogeneic Stem Cell Transplantation for Multiple Myeloma and Myelofibrosis

University of Utah

NCT02501434 SUSPENDED

Aneurysmal Subarachnoid Hemorrhage Trial RandOmizing Heparin

Robert F. James

NCT05067608 COMPLETED

Study on the Safety and Efficacy of Cryopreserved Platelets in Hypoproliferative Thrombocytopenic Patients

Singapore General Hospital

NCT04217148 COMPLETED

The Combination of ATRA and High-dose Dexamethasone as First-line Treatment in Adult Immune Thrombocytopenia

Peking University People's Hospital

NCT03806556 TERMINATED

A Pediatric Trial Using Tranexamic Acid in Thrombocytopenia

Meghan McCormick

NCT02402998 COMPLETED

Eltrombopag in Second Line Adult Primary Immune Thrombosytopenia

Gruppo Italiano Malattie EMatologiche dell'Adulto

NCT00931762 TERMINATED

A Study to Evaluate Safety and Efficacy of Panobinostat in Participants With Primary Myelofibrosis

Novartis Pharmaceuticals

NCT01988506 COMPLETED

Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases

Assistance Publique - Hôpitaux de Paris

NCT01791101 COMPLETED

Eltrombopag in Patients With Delayed Post Transplant Thrombocytopenia.

Gruppo Italiano Malattie EMatologiche dell'Adulto

NCT02323178 COMPLETED

A Study of Eltrombopag in Patients With CMML and Thrombocytopenia

Groupe Francophone des Myelodysplasies

NCT01054443 TERMINATED

A Study to Investigate the Efficacy and Safety of Lusutrombopag (S-888711) Tablets Administered to Adults With Immune Thrombocytopenia (ITP)

Shionogi

NCT01129024 TERMINATED

An Open-label Safety Study of Lusutrombopag (S-888711) in Adults With Chronic Immune Thrombocytopenia (ITP)

Shionogi

NCT03594045 TERMINATED

Efficacy and Safety of Apixaban in the Treatment of Heparin Induced Thrombocytopenia (HIT)

Massachusetts General Hospital

NCT04437953 WITHDRAWN

Avatrombopag for Thrombocytopenia in People With Cancer

Memorial Sloan Kettering Cancer Center

NCT00922883 COMPLETED

A Pilot Study of the Thrombopoietin-Receptor Agonist Eltrombopag in Refractory Aplastic Anemia Patients

National Heart, Lung, and Blood Institute (NHLBI)

NCT01965626 COMPLETED

A Multicenter Randomized Open-label Study of Oseltamivir Combined With HD-DEX Versus HD-DEX in the Management of ITP

Shandong University

NCT04039477 WITHDRAWN

A Phase 2 Study to Evaluate the Safety and Efficacy of KZR-616 in Patients With AIHA and ITP

Kezar Life Sciences, Inc.

NCT01194167 WITHDRAWN

Study of Eltrombopag in Platelet Refractory Thrombocytopenia

University of Cincinnati

NCT02530515 COMPLETED

Ex Vivo-activated Autologous Lymph Node Lymphocytes in Treating Patients With Chronic Lymphocytic Leukemia

M.D. Anderson Cancer Center

NCT03965624 WITHDRAWN

Efficacy and Safety of Ixazomib and Dexamethasone Refractory Autoimmune Cytopenia

Assistance Publique - Hôpitaux de Paris

NCT03195010 TERMINATED

Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia

Fred Hutchinson Cancer Center

NCT01529827 COMPLETED

Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Roswell Park Cancer Institute

NCT02401061 TERMINATED

PRTX-100-202 Open-Label, Dose Escalation Study in Adult Patients With ITP

Protalex, Inc.

NCT01880047 COMPLETED

Safety and Efficacy of Eltrombopag at Escalated Doses

Weill Medical College of Cornell University

NCT01002755 COMPLETED

Lenalidomide and Ofatumumab in Treating Participants With Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

M.D. Anderson Cancer Center

NCT02566603 TERMINATED

PRTX-100-203 Open-Label, Dose Escalation Study in Adult Patients With ITP

Protalex, Inc.

NCT00902018 COMPLETED

Eltrombopag and the Bcl-extra-large (xL) Pathway in Idiopathic Thrombocytopenic Purpura (ITP)

Weill Medical College of Cornell University

NCT00909363 TERMINATED

Thrombocytopenia and Bleeding in Wiskott-Aldrich Syndrome (WAS) Patients

Weill Medical College of Cornell University

NCT01165996 COMPLETED

Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome

Case Comprehensive Cancer Center

NCT02227693 COMPLETED

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Once-daily Oral Avatrombopag in Japanese Subjects With Chronic Liver Diseases and Thrombocytopenia

Eisai Co., Ltd.

NCT01980030 COMPLETED

Using ROMIPLOSTINE for Persistent Thrombocytopenia With Transfusion-dependent Patients Who Received Allogeneic Hematopoietic Stem Cell

Assistance Publique - Hôpitaux de Paris

NCT02298933 COMPLETED

Complement Inhibition Using Eculizumab to Overcome Platelet Transfusion Refractoriness in Patients With Severe Thrombocytopenia

National Heart, Lung, and Blood Institute (NHLBI)

NCT01676961 TERMINATED

Romiplostim in Increasing Low Platelet Counts in Patients With Multiple Myeloma Receiving Chemotherapy

NYU Langone Health

NCT01568333 COMPLETED

A Multi-center Study of Low-dose Decitabine for the Treatment of Immune Thrombocytopenia

Shandong University

NCT01610180 COMPLETED

Eltrombopag for the Treatment of Immune ThrombocytoPenia (ITP) Secondary to Chronic Lymphoproliferative Disorders (LPDs)

Fondazione Progetto Ematologia

NCT02227576 TERMINATED

Prevention of Thrombocytopenia in Glioblastoma Patients

University Hospital, Lille

NCT01355289 COMPLETED

Chronic Hepatitis C Virus Related Thrombocytopenia to Evaluate the Effects of E5501

Eisai Inc.

NCT02845609 COMPLETED

Efficacy of Sialic Acid GNE Related Thrombocytopenia

Hadassah Medical Organization

NCT00914927 COMPLETED

Once-Daily Oral Avatrombopag Tablets Used in Subjects With Chronic Liver Diseases and Thrombocytopenia Prior to Elective Surgical or Diagnostic Procedures

Eisai Inc.

NCT00771810 COMPLETED

Study of Drug to Reduce Thrombocytopenia in Patients Receiving Chemo for Ovarian, Fallopian Tube or Peritoneal Cancer

Tarix Pharmaceuticals

NCT01667263 COMPLETED

The Combination of ATRA and Danazol as Second-line Treatment in Adult Immune Thrombocytopenia

Peking University People's Hospital

NCT00886743 TERMINATED

Study Evaluating The Effects Of Oprelvekin On Cardiac Repolarization In Subjects With Chemotherapy Induced Thrombocytopenia

Pfizer

NCT01153919 TERMINATED

Romiplostim in Treating Hepatitis C-Infected Patients With Thrombocytopenia

University of Southern California

NCT01484314 TERMINATED

Eltrombopag for Thrombocytopenia in Patients With Relapsed Multiple Myeloma

Dana-Farber Cancer Institute

NCT00730314 COMPLETED

Unrelated Hematopoietic Stem Cell Transplantation(HSCT) for Genetic Diseases of Blood Cells

Children's Hospital Los Angeles

NCT02153060 COMPLETED

An Investigation of Dexamethasone With Different Doses in the Management of Immune Thrombocytopenia (ITP)

Shandong University

NCT01976195 WITHDRAWN

High-dose Dexamethasone Combining Thalidomide Versus Dexamethasone Mono-therapy for Management of Newly-diagnosed ITP

Shandong University

NCT01397149 TERMINATED

Eltrombopag in Thrombocytopenic Chronic Lymphocytic Leukemia (CLL) Patients (CLL2S Study of GCLLSG)

University of Ulm

NCT01974401 COMPLETED

Effect of Supragingival Irrigators Containing Chlorhexidine on Oral Health in Blood Dyscrasia

Mashhad University of Medical Sciences

NCT00926354 TERMINATED

Application of AS101 for the Treatment of Thrombocytopenia in Solid Tumor Patients

BioMAS Ltd

NCT06534255 ACTIVE NOT RECRUITING

A Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of MegaLT Injection for Treating Refractory Thrombocytopenia Following Radiotherapy, Chemotherapy, or Transplantation.

Anhui Provincial Hospital

NCT06723106 ENROLLING BY INVITATION

Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial)

Chugai Pharmaceutical

NCT06371417 RECRUITING

Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)

Chugai Pharmaceutical

NCT07490275 NOT YET RECRUITING

Allogeneic CD19/BCMA-Targeted CAR-γδT Cell Therapy: Safety and Preliminary Pharmacodynamics in Relapsed/Refractory Autoimmune Diseases

Institute of Hematology & Blood Diseases Hospital, China

NCT06880081 RECRUITING

Study of PN20 in Adult Patients With Primary Immune Thrombocytopenia (ITP)

Chongqing Peg-Bio Biopharm Co., Ltd.

NCT07315087 RECRUITING

CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases

Institute of Hematology & Blood Diseases Hospital, China

NCT07315373 NOT YET RECRUITING

Optimal Dose of Zanubrutinib to Treat Adult Immune Thrombocytopenia

Peking University People's Hospital

NCT07206758 RECRUITING

Phase I Study of SHR-2173 Injection in Patients With Primary Immune Thrombocytopenia

Guangdong Hengrui Pharmaceutical Co., Ltd

NCT07083960 RECRUITING

OM336 in Autoimmune Cytopenias

Ouro Medicines

NCT06941129 RECRUITING

CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune Diseases

Institute of Hematology & Blood Diseases Hospital, China

NCT07110090 RECRUITING

Umbilical Cord Blood Megakaryocyte Injection (XJ-MK-002) for Cancer Therapy-Induced Thrombocytopenia (CTIT)

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

NCT06826430 RECRUITING

Inaticabtagene Autoleucel Injection in the Treatment of Refractory Systemic Lupus Erythematosus-related Immune Thrombocytopenia

Juventas Cell Therapy Ltd.

NCT05426369 ACTIVE NOT RECRUITING

A Clinical Trial Evaluating SCB-219M in in Chemotherapy-induced Thrombocytopenia (CIT)

Sichuan Clover Biopharmaceuticals, Inc.

NCT07072247 NOT YET RECRUITING

RN1201 Injection in the Treatment of Antibody-Mediated Diseases

The First Affiliated Hospital of Soochow University

NCT06943937 RECRUITING

A Clinical Study of YTS109 Cell in R/R Systemic Lupus Erythematosus

China Immunotech (Beijing) Biotechnology Co., Ltd.

NCT06245746 RECRUITING

UCMSC-Exo for Chemotherapy-induced Myelosuppression in Acute Myeloid Leukemia

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

NCT06534021 NOT YET RECRUITING

IASO-782 in Autoimmune Hematological Diseases

Shanghai IASO Biotechnology Co., Ltd

NCT07599280 NOT YET RECRUITING

Universal STAR-T Cell Injection in R/R Autoimmune Diseases.

Jian Zhu

NCT06521931 COMPLETED

A Study of PN20 for the Prevention of Chemotherapy-induced Thrombocytopenia in Lymphoma or Solid Tumor Patients

Chongqing Peg-Bio Biopharm Co., Ltd.

NCT06291415 WITHDRAWN

The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP)

Hutchmed

NCT06523088 COMPLETED

A Study of PN20 in Healthy Adult Volunteers

Chongqing Peg-Bio Biopharm Co., Ltd.

NCT06148389 COMPLETED

The Safety and Tolerability of STSA-1301 Subcutaneous Injection in Healthy Subjects

Staidson (Beijing) Biopharmaceuticals Co., Ltd

NCT03951623 COMPLETED

The Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMPL-523 in Immune Thrombocytopenia Patients

Hutchison Medipharma Limited

NCT05781906 COMPLETED

Human Mass Balance of [14C]HMPL-523 in Healthy Adult Male Chinese Subjects

Hutchmed

NCT03275740 TERMINATED

A First in HumanTrial to Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-06755347

Pfizer

NCT03394755 COMPLETED

Thrombosomes® in Bleeding Thrombocytopenic Patients

Cellphire Therapeutics, Inc.

NCT05325346 COMPLETED

A Phase I Study of the Co-administration of VLX-1005 and Argatroban in Healthy Human Subjects

Veralox Therapeutics

NCT01286038 TERMINATED

Eltrombopag in Myelodysplastic Syndrome (MDS) Patients With Thrombocytopenia

H. Lee Moffitt Cancer Center and Research Institute

NCT01586455 COMPLETED

Human Placental-Derived Stem Cell Transplantation

New York Medical College

NCT02078284 COMPLETED

Phase 1 Safety Study of Dimethyl Sulfoxide Cryopreserved Platelets

U.S. Army Medical Research and Development Command

NCT02948283 COMPLETED

Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia

City of Hope Medical Center

NCT03603132 COMPLETED

A Study to Evaluate Different Intervals Between Dosing and Feeding on the Pharmacokinetics

Jiangsu HengRui Medicine Co., Ltd.

NCT01963260 COMPLETED

Single Rising Dose Study of MK-8723 in Healthy Participants and Participants With Immune Thrombocytopenia Purpura (MK-8723-001)

Merck Sharp & Dohme LLC

NCT00774358 COMPLETED

Interleukin-2 Treatment for Wiskott-Aldrich Syndrome

Soma Jyonouchi

NCT00903929 COMPLETED

Phase I Study of Eltrombopag for Promoting Thrombopoiesis After Total Body Irradiation

Jane Liesveld

NCT00735930 COMPLETED

Lenalidomide and Alvocidib in Treating Patients With Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

National Cancer Institute (NCI)

NCT02039076 COMPLETED

A Five-Treatment-Period Study to Evaluate the Single-Dose Pharmacokinetics and Pharmacodynamics of Avatrombopag in Healthy Japanese and White Subjects

Eisai Inc.

NCT01345214 TERMINATED

A Study of the Safety and Efficacy of ONO-7746 in Adult Cancer Patients With Chemotherapy Induced Thrombocytopenia

Ono Pharma USA Inc

NCT01549054 COMPLETED

A Study in Healthy Subjects to Evaluate Bioavailability of 4 Formulations of E5501

Eisai Inc.

NCT01289509 COMPLETED

A Study to Evaluate the Relative Bioavailability and Intra-Subject Variability of Two Lots of E5501 40 mg Tablets Administered Twice as Single Oral Doses to Healthy Subjects

Eisai Inc.

NCT01481220 COMPLETED

Safety Study of Eltrombopag Combined With Azacitidine to Treat Myelodysplastic Syndrome (MDS)

Nordic MDS Group

NCT01437384 COMPLETED

Pharmacokinetic and Pharmacodynamic Study in Healthy Subjects Comparing the Interactions Between E5501 and Verapamil and Cyclosporine.

Eisai Inc.

NCT01327872 COMPLETED

Subject Variability in Two Lots of E5501 Administered to Fed and Fasted Healthy Subjects

Eisai Inc.

NCT04518475 RECRUITING

Eltrombopag Combining Rituximab Versus Eltrombopag in the Management of Primary Immune Thrombocytopenia (ITP) in Adults

Institute of Hematology & Blood Diseases Hospital, China

NCT05255003 RECRUITING

STrategies for Anticoagulation in Patients With thRombocytopenia and Cancer-associated Thrombosis

Tzu-Fei Wang

NCT07189910 NOT YET RECRUITING

Sequential rhTPO and Eltrombopag Following Glucocorticoids for Severe Adult ITP

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

NCT07133659 RECRUITING

Exploring the Efficacy, Safety of a Modified Starting Dosage of Avatrombopag in Immune Throbocytopenia (ITP) - a Pilot Study

Al-Mustansiriyah University

NCT06562738 RECRUITING

Clinical Study on Efficacy and Safety of Hetrombopag in the Preoperative Patients of Thrombocytopenia

The Third People's Hospital of Chengdu

NCT03201848 ACTIVE NOT RECRUITING

The Efficacy and Safety of Huaiqihuang Granule in Children With Chronic Primary Immune Thrombocytopenia

Qidong Gaitianli Medicines Co., Ltd

NCT05520892 RECRUITING

Two Regimens of IVIG in the Treatment of Newly Diagnosed ITP in Children

Fujian Medical University Union Hospital

NCT05522465 RECRUITING

Short-course High-dose Prednisone and Dexamethasone in Children With ITP

Fujian Medical University Union Hospital

NCT05944458 COMPLETED

Efficacy of Intravenous N-Acetylcysteine in Preventing Linezolid-Induced Thrombocytopenia in Critically Ill Patients

Helwan University

NCT03119974 COMPLETED

Rate of Prolonged Response After Stopping Thrombopoietin-receptor Agonists Treatment in ITP

Assistance Publique - Hôpitaux de Paris

NCT02267993 COMPLETED

Efficacy and Safety of rhTPO for the Treatment of Thrombocytopenia After Chemotherapy in AML Patients

Institute of Hematology & Blood Diseases Hospital, China

NCT05583838 COMPLETED

A Randomized Trial Comparing Optimized rhTPO Treatment With Eltrombopag Treatment in Pre-treated ITP Pts

Institute of Hematology & Blood Diseases Hospital, China

NCT04638829 COMPLETED

Safety and Treatment Satisfaction in Adults With Chronic ITP After Switching to Avatrombopag From Eltrombopag or Romiplostim

Sobi, Inc.

NCT03866798 TERMINATED

Study to Evaluate the Efficacy and Safety of PANZYGA in Pediatric Patients With Chronic Immune Thrombocytopenia (ITP)

Octapharma

NCT00907478 COMPLETED

Study on Bone Marrow Morphology in Adults Receiving Romiplostim for Treatment of Thrombocytopenia Associated With Immune Thrombocytopenia Purpura (ITP)

Amgen

NCT01727401 TERMINATED

Thromboprophylaxis of Venous Thromboembolism in Acutely-ill Medical Inpatients With Thrombocytopenia

G. d'Annunzio University

NCT00759083 WITHDRAWN

Bivalirudin PCI Registry in Heparin Induced Thrombocytopenia/Heparin Induced Thrombocytopenia and Thrombosis Syndrome (HIT/HITTS) Patients

The Medicines Company

NCT02760251 COMPLETED

Immunomodulation With Romiplostim in Young Adults With ITP

University Hospital, Basel, Switzerland

NCT02556814 COMPLETED

Caffeic Acid Combining High-dose Dexamethasone in Management of ITP

Shandong University

NCT04089267 COMPLETED

Evaluating the Efficacy and Safety of Different Human Thrombopoietin (rhTPO) Regimens in the Treatment of Patients With Primary Immune Thrombocytopenia (ITP)

Shenyang Sunshine Pharmaceutical Co., LTD.

NCT00603824 WITHDRAWN

Fondaparinux in Patients With Acute Heparin-Induced Thrombocytopenia (HIT)

Methodist Healthcare

NCT01789762 COMPLETED

Evaluation of the Efficacy of Platelets Treated With Pathogen Reduction Process

Etablissement Français du Sang

NCT03229746 COMPLETED

Reposition of Second Line Treatment in Chronic Immune Thrombocytopenia

Assiut University

NCT02032134 TERMINATED

Protocol for the Infusion of Buffy Coat-derived Cryopreserved Platelets in Patients With Severe Thrombocytopenia

Napolitano Mariasanta

NCT03258866 COMPLETED

The Study of Different Dose Rituximab in the Treatment of ITP

Shandong University

NCT02642380 WITHDRAWN

Different Cycles of High-dose Dexamethasone for Initial Management of Primary Immune Thrombocytopenia (ITP)

Shandong University

NCT00787332 TERMINATED

A Comparative Sudy Comparing Argatroban® IV vs Desirudin SC for Suspected HIT With or Without Thrombosis Syndrome

Canyon Pharmaceuticals, Inc.

NCT00798525 TERMINATED

Argatroban Versus Lepirudin in Critically Ill Patients

Heinrich-Heine University, Duesseldorf

NCT00888901 COMPLETED

Platelet Function in Idiopathic Thrombocytopenic Purpura (ITP) Patients With Eltrombopag

Ingrid Pabinger, MD

Full Immune Thrombocytopenia Pipeline

Every sponsor, every trial across Phase 1–4. Sortable, filterable, exportable.

Unlock with Pro

Data: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only